About this Journal Submit a Manuscript Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2012 (2012), Article ID 606183, 10 pages
http://dx.doi.org/10.1155/2012/606183
Research Article

Different Effects of Resveratrol on Dose-Related Doxorubicin-Induced Heart and Liver Toxicity

1Medical Biology Unit, Medical University of Lublin, 20-059 Lublin, Poland
2Human Anatomy Department, Medical University of Lublin, 20-059 Lublin, Poland
3Histology and Embryology Department, Medical University of Lublin, 20-059 Lublin, Poland
4Department of Pulmonolgy, Oncology and Alergology, Medical University of Lublin, 20-059 Lublin, Poland
5Clinical Pathomorphology Department, Medical University of Lublin, 20-059 Lublin, Poland
6Department of Toxicology, Poznan University of Medical Sciences, 60-780 Poznan, Poland

Received 18 April 2012; Revised 17 October 2012; Accepted 24 October 2012

Academic Editor: R. Govindarajan

Copyright © 2012 Jaroslaw Dudka et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. M. Fulbright, “Review of cardiotoxicity in pediatric cancer patients: during and after therapy,” Cardiology Research and Practice, vol. 2011, Article ID 942090, 9 pages, 2011.
  2. M. Feola, O. Garrone, M. Occelli et al., “Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin i and brain natriuretic peptide,” International Journal of Cardiology, vol. 148, no. 2, pp. 194–198, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Dudka, F. Burdan, A. Korga et al., “The diagnosis of anthracycline-induced cardiac damage and heart failure,” Postępy Higieny i Medycyny Doświadczalnej, vol. 63, pp. 225–233, 2009. View at Scopus
  4. M. A. Grenier and S. E. Lipshultz, “Epidemiology of anthracycline cardiotoxicity in children and adults,” Seminars in Oncology, vol. 25, no. 4, pp. 72–85, 1998. View at Scopus
  5. L. J. Steinherz, P. G. Steinherz, C. T. C. Tan, G. Heller, and M. L. Murphy, “Cardiac toxicity 4 to 20 years after completing anthracycline therapy,” Journal of the American Medical Association, vol. 266, no. 12, pp. 1672–1677, 1991. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni, “Anthracyclines: molecular advances and pharmacologie developments in antitumor activity and cardiotoxicity,” Pharmacological Reviews, vol. 56, no. 2, pp. 185–229, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Korga, J. Dudka, F. Burdan, J. Sliwinska, S. Mandziuk, and K. Daniwdek-Pietryka, “The redox imbalance and the reduction of contractile protein content in rat hearts administered with L-thyroxine and doxorubicin,” Oxidative Medicine and Cellular Longevity, vol. 2012, Article ID 681367, 9 pages, 2012. View at Publisher · View at Google Scholar
  8. M. F. Xu, P. L. Tang, Z. M. Qian, and M. Ashraf, “Effects by doxorubicin on the myocardium are mediated by oxygen free radicals,” Life Sciences, vol. 68, no. 8, pp. 889–901, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. J. H. Doroshow, “Effect of anthracycline antibiotics on oxygen radical formation in rat heart,” Cancer Research, vol. 43, no. 2, pp. 460–472, 1983. View at Scopus
  10. N. R. Bachur, S. L. Gordon, and M. V. Gee, “A general mechanism for microsomal activation of quinone anticancer agents to free radicals,” Cancer Research, vol. 38, no. 6, pp. 1745–1750, 1978. View at Scopus
  11. J. Vásquez-Vivar, P. Martasek, N. Hogg, B. S. S. Masters, K. A. Pritchard, and B. Kalyanaraman, “Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin,” Biochemistry, vol. 36, no. 38, pp. 11293–11297, 1997. View at Publisher · View at Google Scholar · View at Scopus
  12. M. A. Mansour, A. G. El-Din, M. N. Nagi, O. A. Al-Shabanah, and A. M. Al-Bekairi, “Nω-nitro-L-arginine methylester ameliorates myocardial toxicity induced by doxorubicin,” Journal of Biochemistry and Molecular Biology, vol. 36, no. 6, pp. 593–596, 2003. View at Scopus
  13. R. Nithipongvanitch, W. Ittarat, M. P. Cole, J. Tangpong, D. K. S. Clair, and T. D. Oberley, “Mitochondrial and nuclear p53 localization in cardiomyocytes: redox modulation by doxorubicin (Adriamycin)?” Antioxidants and Redox Signaling, vol. 9, no. 7, pp. 1001–1008, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Zhao, D. McLaughlin, E. Robinson et al., “Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with doxorubicin chemotherapy,” Cancer Research, vol. 70, no. 22, pp. 9287–9297, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Deng, A. Kruger, A. L. Kleschyov, L. Kalinowski, A. Daiber, and L. Wojnowski, “Gp91phox-containing NAD(P)H oxidase increases superoxide formation by doxorubicin and NADPH,” Free Radical Biology and Medicine, vol. 42, no. 4, pp. 466–473, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. S. B. Yee and C. A. Pritsos, “Comparison of oxygen radical generation from the reductive activation of doxorubicin, streptonigrin, and menadione by xanthine oxidase and xanthine dehydrogenase,” Archives of Biochemistry and Biophysics, vol. 347, no. 2, pp. 235–241, 1997. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Dudka, “The role of reactive oxygen and nitrogen species in calcium and iron homeostasis dysregulation in anthracycline cardiotoxicity,” Postępy Higieny i Medycyny Doświadczalnej, vol. 60, pp. 241–247, 2006. View at Scopus
  18. A. E. Crib, M. Peyrou, S. Muruganandan, and L. Schneider, “The endoplasmic reticulum in xenobiotic toxicity,” Drug Metabolism Reviews, vol. 37, no. 3, pp. 405–442, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. J. M. Berthiaume and K. B. Wallace, “Adriamycin-induced oxidative mitochondrial cardiotoxicity,” Cell Biology and Toxicology, vol. 23, no. 1, pp. 15–25, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. V. A. Sardão, P. J. Oliveira, J. Holy, C. R. Oliveira, and K. B. Wallace, “Morphological alterations induced by doxorubicin on H9c2 myoblasts: nuclear, mitochondrial, and cytoskeletal targets,” Cell Biology and Toxicology, vol. 25, no. 3, pp. 227–243, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. U. A. Boelsterli, Mechanistic Toxicology: The Molecular Basis of How Chemicals Disrupt Biological Target, Taylor & Francis, New York, NY, USA, 2003.
  22. S. Zhou, C. M. Palmeira, and K. B. Wallace, “Doxorubicin-induced persistent oxidative stress to cardiac myocytes,” Toxicology Letters, vol. 121, no. 3, pp. 151–157, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. J. M. Berthiaume and K. B. Wallace, “Persistent alterations to the gene expression profile of the heart subsequent to chronic doxorubicin treatment,” Cardiovascular Toxicology, vol. 7, no. 3, pp. 178–191, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. O. A. Al-Shabanah, A. M. Aleisa, M. M. Hafez, and ETAL, “Desferroxamine attenuates doxorubicin induced acute cardiotoxicity through TGF-β/Smad p53 pathway in rat model,” Oxidative Medicine and Cellular Longevity, vol. 2012, Article ID 213112, 7 pages, 2012. View at Publisher · View at Google Scholar
  25. Y. W. Zhang, J. Shi, Y. J. Li, and L. Wei, “Cardiomyocyte death in doxorubicin-induced cardiotoxicity,” Archivum Immunologiae et Therapia Experimentalis, vol. 57, pp. 435–445, 2009.
  26. K. L. Thompson, B. A. Rosenzweig, J. Zhang et al., “Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats,” Cancer Chemotherapy and Pharmacology, vol. 66, no. 2, pp. 303–314, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. A. V. Pointon, T. M. Walker, K. M. Phillips et al., “Doxorubicin in vivo rapidly alters expression and translation of myocardial electron transport chain genes, leads to ATP loss and caspase 3 activation,” PLoS ONE, vol. 5, no. 9, p. e12733, 2010. View at Scopus
  28. K. R. Patel, E. Scott, V. A. Brown, A. J. Gescher, W. P. Steward, and K. Brown, “Clinical trials of resveratrol,” Annals of the New York Academy of Sciences, vol. 1215, pp. 161–169, 2011. View at Publisher · View at Google Scholar
  29. J. M. Smoliga, J. A. Baur, and H. A. Hausenblas, “Resveratrol and health—a comprehensive review of human clinical trials,” Molecular Nutrition and Food Research, vol. 55, no. 8, pp. 1129–1141, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. B. B. Aggarwal, A. Bhardwaj, R. S. Aggarwal, N. P. Seeram, S. Shishodia, and Y. Takada, “Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies,” Anticancer Research, vol. 24, no. 5, pp. 2783–2840, 2004. View at Scopus
  31. Y. A. Rezk, S. S. Balulad, R. S. Keller, and J. A. Bennett, “Use of Resveratrol to improve the effectiveness of cisplatin and doxorubicin: study in human gynecologic cancer cell lines and in rodent heart,” American Journal of Obstetrics and Gynecology, vol. 194, no. 5, pp. e23–e26, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. A. M. Al-Abd, A. M. Mahmoud, G. A. El-Sherbiny, et al., “Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro,” Cell Proliferation, vol. 44, pp. 591–601, 2011. View at Publisher · View at Google Scholar
  33. M. Sato, N. Maulik, and D. K. Das, “Cardioprotection with alcohol: role of both alcohol and polyphenolic antioxidants,” Annals of the New York Academy of Sciences, vol. 957, pp. 122–135, 2002. View at Scopus
  34. S. Das, M. Falchi, A. Bertelli, N. Maulik, and D. K. Das, “Attenuation of ischemia/reperfusion injury in rats by the anti-inflammatory action of resveratrol,” Arzneimittel-Forschung/Drug Research, vol. 56, no. 10, pp. 700–706, 2006. View at Scopus
  35. D. J. Luther, V. Ohanyan, P. E. Shamhart et al., “Chemopreventive doses of resveratrol do not produce cardiotoxicity in a rodent model of hepatocellular carcinoma,” Investigational New Drugs, vol. 29, no. 2, pp. 380–391, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Roy, S. Sannigrahi, S. Majumdar, B. Ghosh, and B. Sarkar, “Resveratrol regulates antioxidant status, inhibits cytokine expression and restricts apoptosis in carbon tetrachloride induced rat hepatic injury,” Oxidative Medicine and Cellular Longevity, vol. 2011, Article ID 703676, 2011.
  37. A. Kumar, C. K. Singh, H. A. Lavoie, D. J. Dipette, and U. S. Singh, “Resveratrol restores Nrf2 level and prevents ethanol-induced toxic effects in the cerebellum of a rodent model of fetal alcohol spectrum disorders,” Molecular Pharmacology, vol. 80, pp. 446–457, 2011.
  38. Z. Ungvari, Z. Bagi, A. Feher et al., “Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2,” American Journal of Physiology, vol. 299, no. 1, pp. H18–H24, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. G. Haskó and P. Pacher, “Endothelial Nrf2 activation: a new target for resveratrol?” American Journal of Physiology, vol. 299, no. 1, pp. H10–H12, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. Z. Cao and Y. Li, “Potent induction of cellular antioxidants and phase 2 enzymes by resveratrol in cardiomyocytes: protection against oxidative and electrophilic injury,” European Journal of Pharmacology, vol. 489, no. 1-2, pp. 39–48, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. E. D. Brookins Danz, J. Skramsted, N. Henry, J. A. Bennett, and R. S. Keller, “Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway,” Free Radical Biology and Medicine, vol. 46, no. 12, pp. 1589–1597, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Szumilo, Wpływ Resweratrolu i Kwasu Protokatecholowego na Rozwój Nowotworów Płaskonabłonkowych Przełyku u Szczura Indukowanych Przez N-Nitrozometylobenzyloaminę, Poland Medical University of Lublin, Lublin, Poland, 2007.
  43. J. A. Crowell, P. J. Korytko, R. L. Morrissey, T. D. Booth, and B. S. Levine, “Resveratrol-associated renal toxicity,” Toxicological Sciences, vol. 82, no. 2, pp. 614–619, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. D. Lebrecht, A. Geist, U. P. Ketelsen, J. Haberstroh, B. Setzer, and U. A. Walker, “Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats,” British Journal of Pharmacology, vol. 151, no. 6, pp. 771–778, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. J. J. Lemasters and A. L. Nieminen, Mitochondria in pathogenesis, Academic/Plenum, New York, NY, USA, 2001.
  46. B. A. Johnson, M. S. Cheang, and G. J. Goldenberg, “Comparison of adriamycin uptake in chick embryo heart and liver cells and murine L5178Y lymphoblasts in vitro: role of drug uptake in cardiotoxicity,” Cancer Research, vol. 46, no. 1, pp. 218–223, 1986. View at Scopus
  47. G. Y. Wang, Y. M. Wang, L. N. Zhang et al., “Effect of resveratrol on heart function of rats with adriamycin-induced heart failure,” Zhongguo Zhongyao Zazhi, vol. 32, no. 15, pp. 1563–1565, 2007. View at Scopus
  48. A. Kasdallah-Grissa, B. Mornagui, E. Aouani et al., “Resveratrol, a red wine polyphenol, attenuates ethanol-induced oxidative stress in rat liver,” Life Sciences, vol. 80, no. 11, pp. 1033–1039, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. P. Vitaglione, B. Ottanelli, S. Milani, F. Morisco, N. Caporaso, and V. Fogliano, “Dietary trans-resveratrol bioavailability and effect on CCl 4-induced liver lipid peroxidation,” Journal of Gastroenterology and Hepatology, vol. 24, no. 4, pp. 618–622, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. G. Şener, N. Topaloǧlu, A. Özer Şehirli, F. Ercan, and N. Gedik, “Resveratrol alleviates bleomycin-induced lung injury in rats,” Pulmonary Pharmacology and Therapeutics, vol. 20, no. 6, pp. 642–649, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Murias, W. Jäger, N. Handler et al., “Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure-activity relationship,” Biochemical Pharmacology, vol. 69, no. 6, pp. 903–912, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. S. S. Leonard, C. Xia, B. H. Jiang et al., “Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses,” Biochemical and Biophysical Research Communications, vol. 309, no. 4, pp. 1017–1026, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Kitada, S. Kume, N. Imaizumi, and D. Koya, “Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1—independent pathway,” Diabetes, vol. 60, no. 2, pp. 634–643, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Dudka, J. Jodynis-Liebert, E. Korobowicz et al., “Activity of NADPH-cytochrome P-450 reductase of the human heart, liver and lungs in the presence of (-)-epigallocatechin gallate, quercetin and resveratrol: an in vitro study,” Basic and Clinical Pharmacology and Toxicology, vol. 97, no. 2, pp. 74–79, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Maier-Salamon, M. Böhmdorfer, T. Thalhammer, T. Szekeres, and W. Jaeger, “Hepatic glucuronidation of resveratrol: interspecies comparison of enzyme kinetic profiles in human, mouse, rat, and dog,” Drug Metabolism and Pharmacokinetics, vol. 26, pp. 364–373, 2011.
  56. R. D. Olson and P. S. Mushlin, “Doxorubicin cardiotoxicity: analysis of prevailing hypotheses,” FASEB Journal, vol. 4, no. 13, pp. 3076–3086, 1990. View at Scopus
  57. Y. Chen, J. T. Saari, and Y. J. Kang, “Weak antioxidant defenses make the heart a target for damage in copper-deficient rats,” Free Radical Biology and Medicine, vol. 17, no. 6, pp. 529–536, 1994. View at Publisher · View at Google Scholar · View at Scopus
  58. R. H. M. Julicher, L. Sterrenberg, G. R. M. M. Haenen, A. Bast, and J. Noordhoek, “The effect of chronic adriamycin treatment on heart kidney and liver tissue of male and female rat,” Archives of Toxicology, vol. 61, no. 4, pp. 275–281, 1988. View at Scopus
  59. B. Piver, M. Fer, X. Vitrac et al., “Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes,” Biochemical Pharmacology, vol. 68, no. 4, pp. 773–782, 2004. View at Publisher · View at Google Scholar · View at Scopus
  60. R. M. Green, M. Graham, M. R. O'Donovan, J. K. Chipman, and N. J. Hodges, “Subcellular compartmentalization of glutathione: correlations with parameters of oxidative stress related to genotoxicity,” Mutagenesis, vol. 21, no. 6, pp. 383–390, 2006. View at Publisher · View at Google Scholar · View at Scopus